Antibody-mediated delivery of viral epitopes to redirect EBV-specific CD8+ T-cell immunity towards cancer cells
Authors:
- Willemijn van der WulpWWWillemijn van der Wulp
- Dennis F. G. RemstDRDennis F. G. Remst
- Michel G. D. KesterMKMichel G. D. Kester
- Paul W. H. I. ParrenPPPaul W. H. I. Parren
- Janine SchuurmanJSJanine Schuurman
- Rob C. HoebenRHRob C. Hoeben
- Maaike E. RessingMRMaaike E. Ressing
- Boris BleijlevensBBBoris Bleijlevens
- Mirjam H. M. HeemskerkMHMirjam H. M. Heemskerk
Open Access
- 9 November 2023
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 31 (1) , 58-68
Abstract
Antibody-mediated delivery of immunogenic epitopes to redirect virus-specific CD8+ T-cells towards cancer cells is an emerging and promising new therapeutic strategy. These so-called antibody-epitope conjugates (AECs) rely on the proteolytic release of the epitopes close to the tumor surface for presentation by HLA class I molecules to eventually redirect and activate virus-specific CD8+ T-cells towards tumor cells. We fused the immunogenic EBV-BRLF1 epitope preceded by a protease cleavage site to the C-terminus of the heavy and/or light chains of cetuximab and trastuzumab. We evaluated these AECs and found that, even though all AECs were able to redirect the EBV-specific T-cells, AECs with an epitope fused to the C-terminus of the heavy chain resulted in higher levels of T-cell activation compared to AECs with the same epitope fused to the light chain of an antibody. We observed that all AECs were depending on the presence of the antibody target, that the level of T-cell activation correlated with expression levels of the antibody target, and that our AECs could efficiently deliver the BRLF1 epitope to cancer cell lines from different origins (breast, ovarian, lung, and cervical cancer and a multiple myeloma). Moreover, in vivo, the AECs efficiently reduced tumor burden and increased the overall survival, which was prolonged even further in combination with immune checkpoint blockade. We demonstrate the potential of these genetically fused AECs to redirect the potent EBV-specific T-cells towards cancer in vitro and in vivo.Keywords
Funding Information
- This work was performed under a grant provided by Genmab.
This publication has 44 references indexed in Scilit:
- High-throughput identification of antigen-specific TCRs by TCR gene captureNature Medicine, 2013
- Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapyBlood, 2013
- Targeted Coating With Antigenic Peptide Renders Tumor Cells Susceptible to CD8+ T Cell-mediated KillingMolecular Therapy, 2013
- Adoptive Transfer of Epstein-Barr Virus (EBV) Nuclear Antigen 1–Specific T Cells As Treatment for EBV Reactivation and Lymphoproliferative Disorders After Allogeneic Stem-Cell TransplantationJournal of Clinical Oncology, 2013
- Crosstalk between Human IgG Isotypes and Murine Effector CellsThe Journal of Immunology, 2012
- T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cellsProceedings of the National Academy of Sciences, 2010
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010
- Cellular Responses to Viral Infection in Humans: Lessons from Epstein-Barr VirusAnnual Review of Immunology, 2007
- IMMUNODOMINANCE IN MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I–RESTRICTED T LYMPHOCYTE RESPONSESAnnual Review of Immunology, 1999
- Monoclonal Antibodies for Analysis of the HLA SystemImmunological Reviews, 1979